Trial reportBMC pharmacology & toxicology2016
Association between aspirin therapy and the outcome in critically ill patients: a nested cohort study.
Trial report in BMC pharmacology & toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Impact of antiplatelet therapy on outcomes of sepsis: A systematic review and meta-analysis.PloS one · 2025Pooled it
- The preventive effect of antiplatelet therapy in acute respiratory distress syndrome: a meta-analysis.Critical care (London, England) · 2018Pooled it
- Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching.Critical care medicine · 2017Pooled it
- Effect of antiplatelet therapy on mortality and acute lung injury in critically ill patients: A systematic review and meta-analysis.Annals of cardiac anaesthesiaPooled it
- Association between β-blocker use and mortality in critically ill patients: a nested cohort study.BMC pharmacology & toxicology · 2018Trial
- Trial
- Thromboxane receptor activation in dendritic cells mitigates sepsis by suppressing S100a8/a9-mediated neutrophil recruitment.Signal transduction and targeted therapy · 2026Article
- Aspirin is associated with improved outcomes in sepsis patients with atrial fibrillation: an analysis of the MIMIC-IV and eICU-CRD databases.Frontiers in cardiovascular medicine · 2026Article
- Mendelian randomization analysis reveals causal associations of serum metabolites with sepsis and 28-day mortality.Scientific reports · 2024Article
- Continuation of chronic antiplatelet therapy is not associated with increased need for transfusions: a cohort study in critically ill septic patients.BMC anesthesiology · 2024Article
- The 125th Anniversary of Aspirin-The Story Continues.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Association of early aspirin use with 90-day mortality in patients with sepsis: an PSM analysis of the MIMIC-IV database.Frontiers in pharmacology · 2024Article
- Association between aspirin and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study based on mimic-IV database.Frontiers in cardiovascular medicine · 2024Article
- Aspirin intervention before ICU admission reduced the mortality in critically ill patients with acute kidney injury: results from the MIMIC-IV.Frontiers in pharmacology · 2023Article
- Aspirin reduces the mortality risk of sepsis-associated acute kidney injury: an observational study using the MIMIC IV database.Frontiers in pharmacology · 2023Article
- Effect of antiplatelet agents onFrontiers in microbiology · 2022Review
- Platelet P2YTH open : companion journal to thrombosis and haemostasis · 2021Article
- Hospitalization for acute coronary syndrome increases the long-term risk of pneumonia: a population-based cohort study.Scientific reports · 2021Article
- Platelets mediate serological memory to neutralize viruses in vitro and in vivo.Blood advances · 2020Article
- Multiple trauma including pelvic fracture with multiple arterial embolization: an autopsy case report.Thrombosis journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiplatelet therapy may attenuate the undesirable effects of platelets on the inflammatory cascades in critical illness. The objective of this study was to evaluate the association between aspirin therapy during intensive care unit (ICU) stay and all-cause mortality.
methodsThis was a nested cohort study within two randomized controlled trials in which all enrolled patients (N = 763) were grouped according to aspirin intake during ICU stay. The primary endpoints were all-cause ICU mortality and hospital mortality. Secondary endpoints included the development of severe sepsis during the ICU stay, ICU and hospital length of stay and the duration of mechanical ventilation. Propensity score was used to adjust for clinically and statistically relevant variables.
resultsOf the 763 patients, 154 patients (20 %) received aspirin. Aspirin therapy was not associated with a reduction in ICU mortality (adjusted OR 1.18, 95 % CI 0.69-2.02, P = 0.55) nor with hospital mortality (adjusted OR 0.95, 95 % CI 0.61-1.50, P = 0.82). Aspirin use had no preferential association with mortality among any of the study subgroups. Additionally, aspirin therapy was associated with higher risk of ICU-acquired severe sepsis, and increased mechanical ventilation duration and ICU length of stay.
conclusionOur study showed that the use of aspirin in critically ill patients was not associated with lower mortality, but rather with an increased morbidity. TRIAL REGISTRATION NUMBER: ISRCTN07413772 and ISRCTN96294863 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.